Longeveron Reports Positive Phase 2b Frailty Data in Cell Stem Cell
Longeveron published positive Phase 2b age-related frailty results in Cell Stem Cell this February, marking a clinical milestone for its cell-based anti-aging therapy. These data position the company within the global longevity biotech market, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034.
1. Phase 2b Age-Related Frailty Results
In February, Longeveron published its Phase 2b age-related frailty trial results in Cell Stem Cell, reporting measurable improvements in clinical frailty scores among older adults. This milestone supports advancement toward later-stage trials and underscores Longeveron’s role in the rapidly expanding longevity biotech sector.
Related News
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
MS
Morgan Stanley to Co-Lead SpaceX’s $1.75T Nasdaq IPO with Four Banks
MS•
AMD
AMD Pledges $10B Taiwan Investment for 2.5D EFB Packaging and Ramps 2nm “Venice” CPUs
AMD•
JEPI
Active ETFs Shift Holdings Daily, Provide Downside Protection, Charge 0.4%-1% Fees
JEPI•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
Sources
F